Medicine
More
-
NEW YORK-- Shares of Valeant Pharmaceuticals International Inc. spiked up Friday afternoon after a report said it might soon buy eye care company Bausch& Lomb Inc. Both comments wouldn't comment.
-
NEW YORK-- Shares of Valeant Pharmaceuticals International Inc. spiked up Friday afternoon after a report said it might soon buy eye care company Bausch& Lomb Inc. Both comments wouldn't comment.
-
The FDA said full clinical information about the patients is still being gathered, but it suggested some of the problems were infections and that "at least one of these infections appears to be fungal in nature." The FDA has since stepped up its oversight of pharmacies that compound drugs tailored to specific patient needs.
-
The FDA said full clinical information about the patients is still being gathered but it suggested that at least some of the problems were caused by infections and "at least one of these infections appears to be fungal in nature."
-
NEW YORK-- Shares of Aveo Oncology sank Friday after the company said its partner Astellas won't ask European Union regulators to approve their kidney cancer pill tivozanib. The disclosure comes three weeks after a panel of Food and Drug Administration advisors recommended the drug not be approved because of its potential health risks.
-
MONTGOMERY, Ala.-- Health officials investigating a cluster of mysterious illnesses in Alabama closed their investigation Thursday after determining the illnesses were unrelated and no new bacteria or viruses were involved. The investigation involved 10 people who became sick and were admitted to hospitals in Dothan and Luverne in southeast Alabama.
-
*Novo shares up 0.7 percent, outperforming sector. COPENHAGEN, May 24- Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
-
WASHINGTON-- The Food and Drug Administration said Thursday it approved a new blood test from Roche to help doctors diagnose diabetes. The FDA said Roche's test is the first to be approved to diagnose the disease.
-
CHICAGO, May 23- U.S. scientists say a dramatic result last year suggesting that a cancer drug already approved by U.S. regulators could quickly clear out Alzheimer's plaques in mice was too good to be true.
-
WARSAW, Poland-- A 33- year-old Polish man received a face transplant just three weeks after being disfigured in a workplace accident, in what his doctors said Wednesday is the fastest time frame to date for such an operation. It was Poland's first face transplant.
-
CHICAGO, May 23- Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
-
*FDA panel says suvorexant safe, effective at lower doses. On Monday, the FDA's internal reviewers published a report expressing concern about suvorexant's potential to cause next-day sleepiness and impaired driving.
-
The advisory panel was convened to help the FDA decide whether to approve the drug, suvorexant, which would be the first in a new class of sedatives designed to help people fall asleep and stay asleep.
-
NEW YORK-- Shares of Regeneron Pharmaceuticals Inc. edged higher on Wednesday on positive clinical trial data for an experimental asthma drug. THE SPARK: The New England Journal of Medicine's website on Tuesday published the results of a study of the asthma treatment dupilumab, which Regeneron is developing with French drugmaker Sanofi.
-
NEW YORK, May 22- Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals. Medicare system contending with new cancer treatments that can exceed $100,000 per patient.
-
NEW YORK-- Shares of Oncolytics Biotech Inc. rose Wednesday after the company reported promising results for its drug Reolysin as a treatment for melanoma, the deadliest form of skin cancer. Oncolytics said it is expanding the trial because of positive early results, as three out of 14 patients had their tumors shrink following treatment with the drug.
-
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease, according to a Citi, which raised its rating on the drugmaker.
-
*Potential sales of $35 bln a year over next 10 years- Citigroup. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.
-
May 21- A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.
-
In a story May 20 about Pfizer Inc. halting a cancer drug study, The Associated Press erroneously reported the uses of two of the drugmaker's existing cancer medicines. Bosulif is approved for use in certain patients with chronic myelogenous leukemia and Inlyta is for advanced kidney cancer.